The most commonly activated pathway in melanoma is the mitogen‐activated protein kinase (MAPK) pathway, often constitutively activated through mutations in the V600 codon of BRAF (in 35–50% of melanomas) and the Q61 codon of NRAS (10–25%) (Tsao et al., 2012). Here, NRAS is linked to melanoma.